NZ596988A - Preparation of nalmefene hydrochloride from naltrexone - Google Patents

Preparation of nalmefene hydrochloride from naltrexone

Info

Publication number
NZ596988A
NZ596988A NZ596988A NZ59698810A NZ596988A NZ 596988 A NZ596988 A NZ 596988A NZ 596988 A NZ596988 A NZ 596988A NZ 59698810 A NZ59698810 A NZ 59698810A NZ 596988 A NZ596988 A NZ 596988A
Authority
NZ
New Zealand
Prior art keywords
naltrexone
preparation
nalmefene hydrochloride
ylide
nalmefene
Prior art date
Application number
NZ596988A
Other languages
English (en)
Inventor
Faveri Carla De
Mauro Casarin
Michele Brusegan
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ596988(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NZ596988A publication Critical patent/NZ596988A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NZ596988A 2009-05-25 2010-05-21 Preparation of nalmefene hydrochloride from naltrexone NZ596988A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900650 2009-05-25
PCT/DK2010/050110 WO2010136039A1 (en) 2009-05-25 2010-05-21 Preparation of nalmefene hydrochloride from naltrexone

Publications (1)

Publication Number Publication Date
NZ596988A true NZ596988A (en) 2013-03-28

Family

ID=43222172

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596988A NZ596988A (en) 2009-05-25 2010-05-21 Preparation of nalmefene hydrochloride from naltrexone

Country Status (35)

Country Link
US (1) US8598352B2 (enExample)
EP (1) EP2435439B8 (enExample)
JP (1) JP5794980B2 (enExample)
KR (1) KR101716522B1 (enExample)
CN (1) CN102459276B (enExample)
AR (1) AR076891A1 (enExample)
AU (1) AU2010252392B2 (enExample)
BR (1) BRPI1010975B1 (enExample)
CA (1) CA2763093C (enExample)
CL (1) CL2011002974A1 (enExample)
CO (1) CO6470832A2 (enExample)
CR (1) CR20110612A (enExample)
DK (1) DK2435439T3 (enExample)
DO (1) DOP2011000362A (enExample)
EA (1) EA019331B1 (enExample)
ES (1) ES2564006T3 (enExample)
GE (1) GEP20146190B (enExample)
HR (1) HRP20160110T1 (enExample)
HU (1) HUE026892T2 (enExample)
IL (1) IL216422A (enExample)
MA (1) MA33368B1 (enExample)
ME (1) ME02622B (enExample)
MX (1) MX2011012502A (enExample)
MY (1) MY158251A (enExample)
NZ (1) NZ596988A (enExample)
PL (1) PL2435439T3 (enExample)
RS (1) RS54599B1 (enExample)
SG (1) SG176205A1 (enExample)
SI (1) SI2435439T1 (enExample)
SM (1) SMT201600061B (enExample)
TN (1) TN2011000590A1 (enExample)
TW (1) TWI469985B (enExample)
UA (1) UA106752C2 (enExample)
WO (1) WO2010136039A1 (enExample)
ZA (1) ZA201108659B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI478928B (zh) 2010-06-11 2015-04-01 Rhodes Technologies 用於製備n-烯丙基化合物之過渡金屬催化的製程及其用途
HRP20170379T1 (hr) 2010-11-05 2017-05-05 H. Lundbeck A/S Postupak proizvodnje naltreksona
CN103012416B (zh) * 2011-09-28 2015-07-01 辽宁海思科制药有限公司 一种盐酸纳美芬的制备方法
TWI560170B (en) 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CN102584840A (zh) * 2011-12-28 2012-07-18 南京优科生物医药有限公司 一种制备纳美芬化合物的方法
WO2013164383A1 (en) 2012-05-03 2013-11-07 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
CN103204859B (zh) * 2013-04-25 2015-12-02 四川海思科制药有限公司 一种盐酸纳美芬化合物及其制备方法
AR096851A1 (es) 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
AU2014368548B2 (en) 2013-12-20 2019-09-19 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
MX2016013889A (es) 2014-04-22 2017-03-09 Otsuka Pharma Co Ltd Medicamento.
CN104513251A (zh) * 2014-11-28 2015-04-15 安徽悦康凯悦制药有限公司 一种盐酸纳美芬的制备方法
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
RU2712232C1 (ru) * 2018-10-05 2020-01-27 Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства Улучшенный способ получения налмефена из налтрексона
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
MX2023005055A (es) 2020-11-02 2023-07-14 Rhodes Tech Proceso de purificacion de noroximorfona.
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法
CN119080788A (zh) * 2024-08-19 2024-12-06 南京海鲸药业股份有限公司 一种盐酸纳美芬杂质的去除监控系统及去除方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4322426A (en) 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US7687646B2 (en) 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene

Also Published As

Publication number Publication date
TWI469985B (zh) 2015-01-21
EA019331B1 (ru) 2014-02-28
MY158251A (en) 2016-09-30
CL2011002974A1 (es) 2012-04-13
CN102459276A (zh) 2012-05-16
MX2011012502A (es) 2011-12-12
CA2763093C (en) 2017-03-07
SMT201600061B (it) 2016-07-01
JP2012527489A (ja) 2012-11-08
WO2010136039A1 (en) 2010-12-02
CO6470832A2 (es) 2012-06-29
EA201171461A1 (ru) 2012-05-30
TN2011000590A1 (en) 2013-05-24
PL2435439T3 (pl) 2016-05-31
HUE026892T2 (en) 2016-07-28
UA106752C2 (uk) 2014-10-10
ME02622B (me) 2017-06-20
US8598352B2 (en) 2013-12-03
SI2435439T1 (sl) 2016-06-30
IL216422A (en) 2015-06-30
IL216422A0 (en) 2012-02-29
AU2010252392B2 (en) 2014-10-23
GEP20146190B (en) 2014-11-10
TW201043634A (en) 2010-12-16
CN102459276B (zh) 2016-09-21
MA33368B1 (fr) 2012-06-01
US20120123123A1 (en) 2012-05-17
AU2010252392A1 (en) 2012-01-12
SG176205A1 (en) 2011-12-29
CR20110612A (es) 2012-02-22
HRP20160110T1 (hr) 2016-03-11
KR101716522B1 (ko) 2017-03-14
RS54599B1 (sr) 2016-08-31
AR076891A1 (es) 2011-07-13
ZA201108659B (en) 2013-02-27
CA2763093A1 (en) 2010-12-02
BRPI1010975A2 (pt) 2015-10-20
DOP2011000362A (es) 2012-07-15
EP2435439A1 (en) 2012-04-04
ES2564006T3 (es) 2016-03-17
KR20120023704A (ko) 2012-03-13
JP5794980B2 (ja) 2015-10-14
BRPI1010975B1 (pt) 2021-08-24
EP2435439B1 (en) 2016-01-06
DK2435439T3 (en) 2016-02-29
EP2435439B8 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
NZ596988A (en) Preparation of nalmefene hydrochloride from naltrexone
GB2472685B (en) Method for making a tool used to manufacture composite parts
PL3147115T3 (pl) Maszyna i sposób wytwarzania kubka
EP2463313A4 (en) METHOD FOR MANUFACTURING COPOLYMER
GB2487877B (en) Method for producing a Beta-Sialon phosphor
EP2453040A4 (en) METHOD FOR MANUFACTURING SHAPED CIRCUIT COMPONENT
IL215357A0 (en) A method for producing bicyclic y-mino acid derivatives
EP2415710A4 (en) PROCESS FOR THE PREPARATION OF BIS (FLUORESULFONYL) IMID
EG26563A (en) Way to produce Dai alkyl ether
GB2474413B8 (en) Method for producing a ß-SiA1ON phosphor
ZA201103786B (en) Method for making a waist relief feature
TW200833649A (en) Method for the preparation of hydroxyadamantanamine
IL220002A0 (en) Method for producing phosphoric acid
PL396441A1 (pl) Sposób wytwarzania mieszaniny gazowej wzbogaconej w wodór
UA106386C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
MY152829A (en) Method for preparing high-purity polyethyleneglycol aldehyde derivatives
PL2242628T3 (pl) Sposób produkcji rur betonowych
PL2480555T3 (pl) Sposoby wytwarzania hydrokodonu, hydromorfonu albo ich pochodnych
IN2012DN01929A (enExample)
PL2456924T3 (pl) Urządzenie łączące dla budowli z gruntu zbrojnego, ściana oporowa i związany z nią sposób
ZA201107567B (en) Method for preparing a superplasticizer
WO2010138298A3 (en) Process for making fill hole in a wall of an energy storage device
PL2608791T3 (pl) Sposób wytwarzania zasady imatynibu
WO2010089267A3 (en) Method for producing 2-halogenomethylphenyl acetic acid derivatives
WO2010018441A3 (en) Process for the preparation of substantially pure telmisartan

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 MAY 2017 BY CPA GLOBAL

Effective date: 20140403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2018 BY CPA GLOBAL

Effective date: 20170407

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2019 BY CPA GLOBAL

Effective date: 20180405

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2020 BY CPA GLOBAL

Effective date: 20190404

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2021 BY CPA GLOBAL

Effective date: 20200410

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2022 BY CPA GLOBAL

Effective date: 20210408

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2023 BY CPA GLOBAL

Effective date: 20220407

LAPS Patent lapsed